Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Olutasidenib→

Olutasidenib Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1887014-12-1
Molecular formula
C18H15ClN4O2
Molecular weight
354.79 g/mol
Drug class
Mutant isocitrate dehydrogenase-1 (IDH1) inhibitortargeted antineoplastic
Mechanism of action
Inhibits mutant IDH1 enzymes, reducing production of the oncometabolite 2-hydroxyglutarate. This promotes differentiation of leukaemic myeloid cells and reduces the abnormal epigenetic signalling driven by mutant IDH1.
Indications / reported uses
  • Treatment of adults with relapsed or refractory acute myeloid leukaemia (AML) with a susceptible IDH1 mutation detected by an FDA-approved test; specialist haematology use

Sources: US DailyMed — REZLIDHIA (olutasidenib) · US FDA prescribing information · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Mutant isocitrate dehydrogenase-1 (IDH1) inhibitor; targeted antineoplastic

Mechanism of action

Inhibits mutant IDH1 enzymes, reducing production of the oncometabolite 2-hydroxyglutarate. This promotes differentiation of leukaemic myeloid cells and reduces the abnormal epigenetic signalling driven by mutant IDH1.

General use cases

  • Treatment of adults with relapsed or refractory acute myeloid leukaemia (AML) with a susceptible IDH1 mutation detected by an FDA-approved test; specialist haematology use

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Olutasidenib Environmental Risk Assessment (ERA) (the Olutasidenib ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.